Canterbury DHB


CNS disease and intrathecal Chemotherapy

All intrathecal chemotherapy must be given in compliance with the CDHB Intrathecal Chemotherapy Policy. Only consultants or senior trainees currently on the CDHB register may prescribe or administer intrathecal chemotherapy.

An initial lumbar puncture is not scheduled until day 24 unless clinically indicated. If overt CNS disease is present intrathecal methotrexate should be given 1-3 times per week until the blasts are no longer present. If transplant is intended do NOT give CNS irradiation.

Imatinib does not penetrate the CNS. Based on data showing dasatinib penetrates the CNS it could be considered preferable in Ph-positive patients with CNS disease.

About this Canterbury DHB document (1656):

Document Owner:

Peter Ganly (see Who's Who)

Last Reviewed:

November 2018

Next Review:

November 2021


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 1656